Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced
today that the Company has signed an option agreement with Cellgate
Inc. of Redwood City, California. This agreement allows Isotechnika
the option to obtain an exclusive license to develop and
commercialize conjugates consisting of Cellgate's patented
transporter technology for the topical delivery of ISA247 in patients
suffering from mild to moderate psoriasis.
Under the terms of the agreement, Cellgate Inc. will perform
studies to evaluate the feasibility of using their technology to
topically deliver ISA247. These studies will commence over the next
few months and are expected to be completed over a one year period.
In exchange for this work, Isotechnika will pay Cellgate Inc. a total
of $500,000USD with $200,000USD paid upfront and the remainder at
predetermined time points. Upon successful completion of the studies,
Isotechnika has the option to license the technology from Cellgate
Inc. to further develop and commercialize conjugates for topical
delivery of ISA247.
"We are excited to be working with a company whose drug is showing
great promise in the systemic treatment of psoriasis," commented Dr.
Linda Sonntag, Cellgate Inc.'s Chairman. "It is our hope and
expectation that Cellgate's transporter technology will safely and
efficaciously expand ISA247's use to the 65% of patients with mild
psoriasis and supplement those with moderate to severe psoriasis via
"The opportunity to collaborate with Cellgate is very worthwhile,"
stated Dr. Randall Yatscoff, Isotechnika's President and Chief
Executive Officer. "If successful, this could allow us to expand our
drug's use beyond the moderate and severe forms of psoriasis
currently being tested with systemic ISA247 into the milder cases of
psoriasis. The development of a topically administered ISA247 product
would allow us to optimize the market potential for our drug by
making ISA247 available for mild to severe cases of psoriasis."
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world-class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 is an immunosuppressant
currently in an extension protocol of a Canadian Phase III human
clinical trial for the treatment of moderate to severe psoriasis. In
addition, ISA247 has successfully completed a Phase IIa trial for
kidney transplantation. The Company also has an additional
immunosuppressive compound in its drug pipeline, TAFA93 which is in
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
About Cellgate Inc.
Cellgate Inc. is a privately held clinical stage biopharmaceutical
company headquartered in Redwood City, California. Cellgate Inc.
leverages its expertise in molecular transporters and drug
development to efficiently advance a broad portfolio of novel
polyamine analog anti-proliferation therapeutics.
This press release may contain forward-looking statements.
Forward- looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward- looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.
ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.ch
Dr. Randall Yatscoff, President & CEO, Isotechnika Inc., Tel:
+1-780-487-1600 ext. 246, Fax: +1-780-484-4105, E-mail:
firstname.lastname@example.org; Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., Tel: +1-780-909-4661,
Fax: +1-780-484-4105, E-mail: email@example.com; To
request a free copy of this organization's annual report, please go
to http://www.newswire.ca and click on Tools for Investors.